GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (STU:25I) » Definitions » Long-Term Debt

ImmuPharma (STU:25I) Long-Term Debt : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2012. Start your Free Trial

What is ImmuPharma Long-Term Debt?

ImmuPharma's Long-Term Debt for the quarter that ended in Jun. 2023 was €0.00 Mil.


ImmuPharma Long-Term Debt Historical Data

The historical data trend for ImmuPharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Long-Term Debt Chart

ImmuPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 - - - -

ImmuPharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ImmuPharma  (STU:25I) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


ImmuPharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of ImmuPharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuPharma (STU:25I) Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (STU:25I) Headlines

No Headlines